List of Excipients in Branded Drug BALCOLTRA

« Back to Dashboard

Balcoltra Excipient Strategy, Formulation IP, and Commercial Opportunities

Last updated: September 24, 2026

Balcoltra is a 28-day oral contraceptive containing levonorgestrel, ethinyl estradiol, and ferrous bisglycinate. Its commercial differentiation depends less on novel excipients than on the coordinated use of excipients, tablet color, packaging, dose sequencing, and iron-containing tablets. The strongest opportunities are generic or authorized-generic development, low-cost reformulation, improved gastrointestinal tolerability, and adherence-focused packaging.

What is Balcoltra and how is it formulated?

Balcoltra is an oral contraceptive product marketed under FDA NDA 209574. Each 28-day regimen contains 21 hormone tablets and seven brown tablets containing ferrous bisglycinate. The hormone tablets contain 0.1 mg levonorgestrel and 0.02 mg ethinyl estradiol. The brown tablets do not provide contraceptive hormones but contain iron as ferrous bisglycinate.[1]

Product element	Balcoltra composition	Commercial function
White active tablets	Levonorgestrel 0.1 mg; ethinyl estradiol 0.02 mg	Hormonal contraception
Brown tablets	Ferrous bisglycinate, equivalent to 25 mg elemental iron per tablet	Supports the 28-day dosing sequence
Regimen	21 active tablets followed by seven brown tablets	Maintains daily tablet-taking behavior
Dosage form	Immediate-release oral tablets	Conventional generic pathway
Administration	One tablet daily in sequence	Adherence depends on packaging and tablet identification

Ferrous bisglycinate is an active ingredient in the brown tablets, not merely an excipient. This distinction matters for regulatory strategy, bioequivalence, manufacturing controls, and product labeling.

What excipients are used in Balcoltra tablets?

Balcoltra uses conventional oral-tablet excipients disclosed in the FDA prescribing information. The formulation includes lactose monohydrate, microcrystalline cellulose, povidone, croscarmellose sodium, magnesium stearate, and colorants associated with the tablet presentation.[1]

The excipient system performs four principal functions:

1. Lactose monohydrate and microcrystalline cellulose provide tablet bulk and support compression.
2. Povidone acts as a binder.
3. Croscarmellose sodium supports rapid tablet disintegration.
4. Magnesium stearate functions as a lubricant.

The product also uses color differentiation between the hormone tablets and the iron-containing tablets. The color system is commercially important because a 28-day contraceptive regimen depends on correct tablet order.

Which excipients create the greatest development risk?

The principal formulation risks are not unusual excipient toxicity issues. They are process and performance risks:

• Hormone-dose uniformity at low drug loading.
• Segregation of levonorgestrel and ethinyl estradiol during blending.
• Lubrication sensitivity caused by magnesium stearate.
• Compression defects in small tablets.
• Disintegration changes caused by excessive lubricant or binder.
• Color consistency across manufacturing lots.
• Iron-related discoloration, taste, and stability concerns.
• Cross-contamination controls between hormone and iron-tablet manufacturing.

The low-dose hormone formulation requires tighter blend uniformity controls than a conventional high-dose tablet. Small changes in particle size, density, mixing time, or lubricant concentration can affect assay uniformity and dissolution.

What excipient strategy is most commercially attractive for Balcoltra?

The most practical strategy is a conservative, bioequivalence-oriented formulation that retains the functional roles of the reference-product excipients while allowing supplier and process flexibility.

Strategy 1: Reference-like generic formulation

A generic developer can use lactose, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate. This approach reduces formulation risk and supports a conventional ANDA development program under FDA requirements for pharmaceutical equivalence and bioequivalence.[2]

The main advantages are:

• Familiar excipient safety profiles.
• Established compendial specifications.
• Broad supplier availability.
• Straightforward tablet manufacturing.
• Lower risk of unexpected dissolution differences.

The principal disadvantage is limited differentiation. A reference-like formulation competes primarily on price, availability, packaging, and distribution.

Strategy 2: Direct-compression formulation

A direct-compression platform could replace or reduce wet-granulation dependence through co-processed microcrystalline cellulose, lactose grades, or spray-dried excipients. This may reduce process steps and manufacturing cost.

The technical challenge is maintaining content uniformity for the low-dose hormones. Direct compression is commercially attractive only if the formulation provides adequate powder flow and segregation resistance.

Strategy 3: Low-moisture formulation

A low-moisture process using anhydrous lactose, low-moisture microcrystalline cellulose, or a dry granulation step could improve stability where moisture affects tablet hardness, dissolution, or hormone assay.

This strategy may be useful for contract manufacturers operating in humid environments. It also can reduce drying time and improve batch-cycle efficiency. The tradeoff is possible loss of compactability or increased tooling pressure.

Strategy 4: Improved iron-tablet formulation

The brown tablets create a separate product-development opportunity. Ferrous bisglycinate is generally selected for tolerability and bioavailability considerations, but the tablet still requires control of odor, taste, color migration, and mechanical strength.

Possible approaches include:

• Film coating to reduce metallic taste.
• Modified colorant systems with improved light stability.
• Lower-dusting iron premixes.
• Excipients that reduce tablet-to-tablet color variation.
• Dedicated equipment or validated cleaning procedures for iron-containing material.

Any change to the iron tablet must preserve the labeled elemental iron content and the product’s established appearance and regimen.

What formulation patents protect Balcoltra?

Publicly available product information identifies Balcoltra as an FDA-approved combination product, but the commercial value of its excipient system does not appear to depend on a clearly differentiated, broad excipient patent platform. The principal protectable elements are more likely to involve the combination, dosage regimen, tablet sequence, ferrous bisglycinate component, and manufacturing specifications than ownership of common excipients.

Potential protection area	Strategic relevance
Levonorgestrel/ethinyl estradiol combination	Core active pharmaceutical product
Ferrous bisglycinate in the 28-day regimen	Product differentiation and formulation complexity
Tablet sequence and color coding	Adherence and product presentation
Specific excipient ranges	Potential formulation claims if supported by patent disclosures
Dissolution or stability profile	Possible process or formulation claim scope
Packaging configuration	Adherence and product-identity protection
Manufacturing controls	Operational barrier rather than broad market exclusivity

A generic applicant would normally assess Orange Book-listed patents and exclusivity, then review issued and pending patents covering the active combination, ferrous bisglycinate tablets, dosage regimen, formulation, and manufacturing process. FDA’s Orange Book identifies patents and regulatory exclusivity associated with approved products, but it does not capture every potentially relevant patent outside the listed product claims.[3]

When does Balcoltra lose exclusivity?

Balcoltra received FDA approval in 2018. The product’s regulatory exclusivity and any Orange Book-listed patents must be evaluated separately. FDA approval alone does not establish the date on which all market barriers end.

For a generic entrant, the key dates are:

Barrier	Relevance to Balcoltra
Five-year NCE exclusivity	Generally unlikely to apply if the product uses previously approved active ingredients
Three-year clinical-investigation exclusivity	Could apply if approval relied on qualifying new clinical investigations
Orange Book patents	May delay approval or launch depending on patent term and litigation
Pediatric exclusivity	Would add six months if granted
Formulation or regimen patents	Could affect launch even where composition patents are weak
ANDA approval	Requires pharmaceutical equivalence and bioequivalence

A Paragraph IV certification could trigger patent litigation under the Hatch-Waxman Act if an applicant asserts that a listed patent is invalid, unenforceable, or not infringed. The filing of a patent-infringement action within the statutory period can impose a 30-month stay on FDA approval, subject to statutory exceptions and court developments.[4]

What generic entry risks exist for Balcoltra?

Balcoltra has a relatively accessible generic-development profile because it is an immediate-release oral tablet using established active ingredients. The principal risk is not scientific feasibility. It is the need to reproduce a multi-tablet regimen with consistent hormone content, iron content, appearance, dissolution, and packaging.

Generic launch scenarios

Scenario	Likely commercial effect
Single ANDA entrant	Moderate price pressure; incumbent may retain preferred distribution
Multiple ANDA entrants	Rapid erosion in pharmacy and payer channels
Authorized generic	Greater control over pricing and channel segmentation
Formulation-differentiated generic	Potential premium for tolerability or adherence
Private-label launch	Higher volume, lower unit margin
Delayed entry from patent litigation	Continued branded pricing during the stay period

A conventional generic may be able to substitute for Balcoltra if it satisfies FDA requirements for pharmaceutical equivalence and bioequivalence. However, packaging and tablet sequence are important because an apparently minor difference in tablet color or blister configuration can increase medication-error risk.

What FDA regulatory issues affect Balcoltra excipient development?

FDA review will focus on pharmaceutical equivalence, bioequivalence, manufacturing controls, stability, impurities, and labeling consistency. The formulation must also comply with inactive-ingredient expectations for oral solid dosage forms.[2,5]

Key regulatory workstreams include:

• Establishing blend uniformity for low-dose hormones.
• Demonstrating dissolution equivalence for the active tablets.
• Confirming elemental iron content in the brown tablets.
• Validating color and physical-appearance specifications.
• Assessing nitrosamines and other process-related impurities where applicable.
• Demonstrating stability under long-term and accelerated conditions.
• Controlling cleaning validation for hormone and iron materials.
• Verifying packaging protects tablets from moisture, light, and mechanical damage.

A formulation that changes excipient type or concentration may remain eligible for an ANDA, but the applicant must show that the change does not alter product performance or create a clinically meaningful difference. A major change in dosage form, release profile, or active ingredient presentation could require a different regulatory pathway.

How strong is the Balcoltra patent estate?

The product’s patent strength is likely moderate to weak if evaluated solely on common excipients. Lactose, microcrystalline cellulose, povidone, croscarmellose sodium, and magnesium stearate are widely used and difficult to protect through broad composition claims.

Potentially stronger protection would require narrow claims directed to:

• The specific hormone and ferrous bisglycinate combination.
• A defined 21-plus-seven tablet regimen.
• A particular tablet sequence or color architecture.
• Specific stability or dissolution performance.
• A manufacturing process that solves content-uniformity or segregation problems.
• A packaging system that controls regimen errors.

Those claims would still face validity and obviousness challenges if similar contraceptive regimens or iron-containing placebo tablets are disclosed in prior art.

What licensing and partnership opportunities exist?

The strongest commercial opportunities are manufacturing and distribution partnerships rather than excipient licensing.

Contract manufacturing

A contract development and manufacturing organization could offer:

• Low-dose hormone blending and tableting.
• Separate iron-tablet manufacturing.
• Integrated blister packaging.
• Cleaning validation for hormone and iron products.
• Regional supply for generic or private-label versions.

Excipient supplier partnerships

Suppliers could position specialized grades of:

• Low-moisture lactose.
• Co-processed direct-compression excipients.
• Low-segregation microcrystalline cellulose.
• High-efficiency superdisintegrants.
• Taste-masking coating systems.
• Iron-compatible colorant systems.

The value proposition must be measurable through lower tablet weight, improved content uniformity, shorter processing time, reduced rejects, or better stability. A generic excipient substitution without a validated manufacturing advantage is unlikely to support premium pricing.

Brand or authorized-generic licensing

A licensee could acquire rights to manufacture or distribute Balcoltra under a regional commercial agreement. Value would depend on remaining exclusivity, existing channel access, prescription volume, manufacturing cost, and the likelihood of ANDA competition. Product-level revenue and licensing economics are not established by the FDA label or Orange Book records.

How does Balcoltra compare with conventional combined oral contraceptives?

Balcoltra differs from standard 21/7 oral contraceptives because the seven non-hormonal tablets contain ferrous bisglycinate rather than being inert placebos.

Attribute	Balcoltra	Conventional combined oral contraceptive
Hormonal tablets	21	Commonly 21 or 24
Non-hormonal tablets	Seven iron-containing tablets	Inert placebo or no tablets
Excipient complexity	Higher because of iron tablets	Usually lower
Manufacturing segregation risk	Higher	Lower
Adherence design	Daily 28-day sequence	Varies by product
Generic formulation burden	Moderate	Low to moderate
Differentiation	Iron-containing regimen	Often limited to dose, brand, or packaging

The iron-containing tablets create a defensible commercial narrative but also add cost and manufacturing complexity. A generic developer can exploit that complexity if it has efficient iron handling, robust packaging, and validated low-dose hormone processing.

Key Takeaways

• Balcoltra combines levonorgestrel, ethinyl estradiol, and ferrous bisglycinate in a 28-day oral regimen.
• Its excipient system is conventional, with lactose, microcrystalline cellulose, povidone, croscarmellose sodium, magnesium stearate, and colorants.
• Ferrous bisglycinate is an active component of the brown tablets, not an excipient.
• The most important formulation risks are low-dose hormone uniformity, iron-tablet handling, color control, dissolution, and packaging sequence.
• Generic entry is technically feasible through an ANDA, but product presentation and regimen integrity require careful development.
• Excipient suppliers have the strongest opportunity in low-segregation, low-moisture, direct-compression, and iron-compatible platforms.
• Broad patent protection based on common excipients is unlikely to be strong. Narrow claims covering regimen, formulation ranges, manufacturing, or packaging would carry greater commercial value.
• Patent expiration, Paragraph IV exposure, and launch timing depend on the current Orange Book listing and any relevant litigation or settlement agreements.

FAQs About Balcoltra Excipient and Commercial Strategy

Does Balcoltra contain iron as an excipient?

No. The brown tablets contain ferrous bisglycinate as an active ingredient providing elemental iron. It is part of the labeled product composition.

Can a generic Balcoltra use different excipients?

Yes, provided the generic meets FDA requirements for pharmaceutical equivalence, bioequivalence, quality, stability, and labeling. Different excipients may affect dissolution, content uniformity, and tablet appearance.

Is Balcoltra an extended-release formulation?

No. Balcoltra is an immediate-release oral tablet product. Its commercial complexity comes from the multi-tablet regimen, not modified drug release.

Why are Balcoltra’s brown tablets commercially important?

They contain ferrous bisglycinate and complete the 28-day daily dosing sequence. Their color and position in the package help distinguish them from the hormone tablets.

Can an excipient company patent a Balcoltra-compatible formulation?

Potentially, but broad claims covering standard excipients are unlikely to be commercially strong. More valuable claims would require a specific, demonstrated improvement in content uniformity, stability, dissolution, manufacturability, or iron-tablet performance.

References

1. U.S. Food and Drug Administration. (2018). Balcoltra (levonorgestrel, ethinyl estradiol, and ferrous bisglycinate) tablets: Prescribing information. FDA/DailyMed.

2. U.S. Food and Drug Administration. (2020). ANDAs for certain highly purified synthetic peptides: Product-specific guidance and general pharmaceutical equivalence requirements. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

4. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).

5. U.S. Food and Drug Administration. (2019). Inactive ingredient database. FDA.